

## Effect of experimentally induced thyrotoxicosis on oxidative energy metabolism in rat heart mitochondria

S. S. KATYARE† and F. R. BILLIMORIA\*§

Biochemistry Division, Bhabha Atomic Research Centre, Trombay, Bombay 400 085, India  
\*Department of Biochemistry, L. T. M. Medical College and L. T. M. G. Hospital, Sion, Bombay 400 022, India

†Present Address: Department of Biochemistry, Faculty of Science, M. S. University of Baroda, Baroda 390 002, India

MS received 26 October 1988; revised 7 August 1989

**Abstract.** Treatment of rats with T<sub>3</sub> resulted in a significant decrease in body weight, while the heart weight increased. T<sub>4</sub> treatment had less marked effect on body weights but resulted in decreased heart weights. Serum T<sub>4</sub> levels decreased significantly with simultaneous increase of T<sub>3</sub> level following T<sub>3</sub> treatment, whereas with T<sub>4</sub> treatment, levels of both T<sub>4</sub> and T<sub>3</sub> increased in the serum. Low doses of T<sub>3</sub> (0.5 µg) caused decrease in mitochondrial protein content while high dose of T<sub>4</sub> (1 µg), caused significant increase in mitochondrial mass. The state 3 respiration rates were significantly depressed following T<sub>3</sub> and T<sub>4</sub> treatments, in a substrate specific manner with the effects being more pronounced with T<sub>3</sub>; these responses with T<sub>4</sub> were dose-dependent for succinate and ascorbate + N,N,N',N'-tetramethyl-*p*-phenylenediamine. State 4 respiration rates also exhibited similar corresponding changes. ADP/O ratios were not changed but ADP-phosphorylation rates were decreased significantly particularly so with the T<sub>3</sub>-treated animals. Treatment with T<sub>3</sub> also resulted in lowering of intramitochondrial cytochrome contents. Similar effects were seen also with higher doses of T<sub>4</sub>. The results thus indicate that T<sub>3</sub>- and T<sub>4</sub>-thyrotoxicosis results in impaired energy metabolism in heart mitochondria.

**Keywords.** Thyrotoxicosis; heart mitochondria; energy metabolism.

### Introduction

Role of thyroid hormones in regulation of mitochondrial energy metabolism and their energy-linked functions and on the basal metabolic rate (BMR) is now well established (Tata *et al.*, 1963; Tata, 1964; Gustafsson *et al.*, 1965; Oppenheimer *et al.*, 1976; Oppenheimer, 1979; Bernal and De Groot, 1980). Deficiency of thyroid hormones causes decrease in metabolism with concomitant lowering of the basal metabolic rate (Tata, 1964). Treatment of hypothyroid animals with thyroid hormones restores these activities to normal or near normal levels, which is also accompanied by increase in the concentrations of specific respiratory components such as cytochromes and protein synthesis (Tata *et al.*, 1963; Tata, 1964; Gustafsson *et al.*, 1965; Katyare *et al.*, 1970).

Thyrotoxicosis—a condition of excessive levels of thyroid hormones—on the other hand, increases BMR and causes fast pulse (tachycardia), anxiety, palpitation, increased sweating, loss of weight, general muscular weakness, elevation of

§ To whom all correspondence should be addressed.

Abbreviations used: BMR, Basal metabolic rate; MOPS, 3-(N-morpholino) propanesulfonic acid; TMPD, N, N, N', N'-tetramethyl-*p*-phenylenediamine; RIA, radioimmunoassay; RCR, respiratory control ratios; T<sub>3</sub>, 3,3',5-triiodo-L-thyronine; T<sub>4</sub>, L-thyroxine.

lysosomal cathepsin D activity and uncoupling of oxidative phosphorylation, which results in hyperthermia (Williams and Bakke, 1962; Johansen *et al.*, 1978; Irvine *et al.*, 1979; De Visscher and Burger, 1980; Jabbari and Huot, 1980; Satav and Katyare, 1981, 1982). Many reports are available on the effects of thyrotoxicosis on energy metabolism in mitochondria from tissues such as liver, kidney, brain and skeletal muscle (Maley and Lardy, 1953; Hoch and Lipmann, 1954; Dow, 1967; Stocker *et al.*, 1968; Winder *et al.*, 1975; Winder and Holloszy, 1977; Satav and Katyare, 1981, 1982). It has been shown that excessive levels of thyroid hormones affect the rates of coupled phosphorylation, ADP/O ratios, cytochrome contents and ATPase activity in mitochondria (Winder *et al.*, 1975; Winder and Holloszy, 1977; Satav and Katyare, 1982).

The effects of thyroid hormones on energy metabolism in the heart are not well understood. Tachycardia associated with thyrotoxicosis is accompanied by persistent atrial fibrillation resulting in transient episodes of arrhythmia (Hoffman and Lowery, 1960). Recent studies indicate that congestive heart failure can be produced in experimental animals by administering thyroxine (Shapiro *et al.*, 1975) and that infants with neonatal thyrotoxicosis without underlying cardiac disease may develop congestive heart failure (Shapiro *et al.*, 1975). The frequency of mitral valve prolapse is twice as much in hyperthyroid than in euthyroid individuals (Channide *et al.*, 1981).

The energy metabolism of the heart relates essentially to the contractile mechanisms of the myofibrils and oxidative phosphorylation in the mitochondria (Mela-Riker and Bukoski, 1985). In the present study an attempt has therefore been made to assess the effect of thyrotoxicosis on energy metabolism in heart by studying mitochondrial oxidative phosphorylation using experimental animal model. Results of the present studies together with those on altered membrane structure-function relationships (Dave *et al.*, 1989) have helped in illustrating and explaining the underlying biochemical lesions in heart pathology.

## Materials and methods

### Chemicals

Sodium salts of succinic acid, L-glutamic acid and ascorbic acid as well as 3,3', 5-triiodo-L-thyronine ( $T_3$ ), L-thyroxine ( $T_4$ ), ADP, rotenone, Triton X-100, 3-(N-morpholino) propanesulfonic acid (MOPS), EDTA, EGTA and bovine serum albumin were purchased from Sigma Chemical Co., St. Louis, Missouri, USA. N,N,N,N'-tetramethyl-*p*-phenylenediamine (TMPD) was from British Drug Houses, Poole, Dorset, UK. All other chemicals used were of analytical-reagent grade. Radioimmunoassay (RIA) kits for thyroxine (code RIA-K5) and triiodothyronine (code RIA-K4) were obtained from the Radiopharmaceuticals Division of Bhabha Atomic Research Centre, Bombay.

### Animals

Male albino rats of Wistar strain of average weight  $205.0 \pm 4.4$  g were used. The rats were made thyrotoxic by injecting subcutaneously 0.5 or 1  $\mu$ g of L- $T_3$  or L- $T_4$ /g

body weight (dissolved in 0.9% NaCl solution containing 5 mM NaOH) per day for 4 days (Carter *et al.*, 1981, 1982; Satav and Katyare, 1981, 1982). The animals were killed on the 5th day. Control animals received the corresponding amounts of saline vehicle. Concentrations of the hormones were adjusted such that the animals received 100  $\mu$ l of hormone solution or saline vehicle per 100 g body weight. A record of initial and final body weights together with heart weight of both normal and thyrotoxic animals was maintained.

#### *Serum T<sub>3</sub> and T<sub>4</sub>*

Serum samples were collected from control and thyrotoxic animals on the fifth day of the treatment and the contents of T<sub>4</sub> and T<sub>3</sub> in the sera were determined by RIA.

#### *Isolation of mitochondria*

Isolation of rat heart mitochondria was carried out essentially by the procedure described earlier (Doussiere *et al.*, 1984; Katyare, S. S., Rajan, R. R. and Gopalswamy, U. V., unpublished results). The rats were killed by decapitation and their hearts were quickly removed and placed in beakers containing chilled isolation medium (0–4°C), consisting of 0.225 M mannitol, 0.075 M sucrose and 1 mM EDTA, pH 7.4. The tissue was washed repeatedly with the isolation medium to free it from blood and was minced into small pieces (1.5 × 1.5 mm) and homogenized in a glass teflon Potter-Elvehjem homogenizer (wall clearance 0.18 mm) giving two up and down strokes. The homogenate (10% w/v) was centrifuged at 700 g for 10 min in a Sorvall RC5-C refrigerated centrifuge (0–4°C) to sediment nuclei and cell debris. The supernatant was subjected to a further centrifugation at 10,000 g for 10 min to sediment mitochondria. The mitochondrial pellet was washed once. Finally, the mitochondrial pellet obtained from 1 g of tissue was suspended in 1 ml of isolation medium and was used for the study of oxidative phosphorylation and measurement of cytochrome contents. All operations were carried out at 0–4°C.

#### *Oxidative phosphorylation*

Measurements of coupled phosphorylation were carried out at 25°C with a Clark type oxygen electrode essentially as described by Katyare *et al.* (1977). The medium (in a total volume of 1.3 ml) contained 225 mM sucrose, 20 mM KCl, 1 mM EGTA, 10 mM MOPS buffer (pH 7.4), 5 mM potassium phosphate buffer pH 7.4 and approximately 1 mg of mitochondrial protein. Concentrations of the substrates used were: glutamate (10 mM), pyruvate + malate (10+1mM), succinate (10 mM) and ascorbate (10 mM) plus TMPD (0.1 mM); with succinate and ascorbate + TMPD, 1  $\mu$ M rotenone was also included in the reaction medium. About 150–250 nmol of AD P in 10–20  $\mu$ l were added, and the rates of respiration in the presence of ADP (state 3) and after its depletion (state 4) were recorded. ADP/O ratios and the ADP-phosphorylation rates were calculated as described (Ferreira and Gil, 1984; Katyare *et al.*, 1977).

*Mitochondrial cytochrome contents*

Approximately 6–10 mg of mitochondrial proteins were solubilized using freshly prepared Triton X-100 solution at a final concentration of 0.1% and the volume was made up to 6 ml with isolation medium in which 10 mM potassium phosphate buffer pH 7.4 was also included. The difference spectra of dithionite-reduced minus ferricyanide-oxidized cytochromes were recorded as described by Satav and Katyare (1982). Contents of intra-mitochondrial cytochromes were calculated using the wavelength pairs and extinction coefficients for cytochromes  $aa_3$ , b and c +  $c_1$ , respectively, as described (Satav and Katyare, 1982).

Protein was estimated by the method of Lowry *et al.* (1951).

**Results**

The effects of  $T_3$ - and  $T_4$ -induced thyrotoxicosis on the body weights of the animals and heart weight are summarised in table 1. It is evident that treatment with  $T_3$  brought about significant decrease in the body weights (17.8 and 28.0% decrease respectively for two doses employed). Treatment with  $T_4$  was less effective and resulted in 8.5 and 16.7% decrease respectively with the two doses. The results thus emphasize the catabolic role played by  $T_3$  in the experimental thyrotoxicosis. Similar findings have been reported by earlier research workers (Winder *et al.*, 1975; Satav and Katyare, 1982; Cote' and Boulet, 1985).

**Table 1.** Effect of thyrotoxicosis on body weight and heart weight.

Treatment	Body weight (g)	Heart weight	
		(g)	Body weight (%)
Control (12)	250.4 ± 3.3	0.863 ± 0.011	0.344 ± 0.006
0.5 µg $T_3$ (10)	205.9 ± 5.3***	1.149 ± 0.039***	0.556 ± 0.016***
1.0 µg $T_3$ (10)	180.0 ± 2.1***	0.990 ± 0.010***	0.551 ± 0.008***
0.5 µg $T_4$ (10)	229.1 ± 7.0**	0.878 ± 0.020 <sup>NS</sup>	0.385 ± 0.007***
1.0 µg $T_4$ (19)	208.7 ± 4.3***	0.679 ± 0.016***	0.326 ± 0.005*

Animals were given  $T_3$  or  $T_4$  (dissolved in 0.9 % NaCl containing 5 mM NaOH) in doses indicated/g body weight subcutaneously for 4 consecutive days.

Results are given as means ± SEM of the number of observations indicated in the parentheses.

\* $P < 0.05$ , \*\* $P < 0.02$  and \*\*\* $P < 0.001$  compared with control.

NS, Not significant.

Thyrotoxicosis also brought about marked changes in the heart weight in these animals (table 1). Thus treatment with  $T_3$  resulted in cardiac hypertrophy and the absolute weight of the heart tissue increased by 15–33% with the lower dose of  $T_3$  being more effective than the higher dose. The effects of  $T_4$  treatment were less marked. Cardiac hypertrophy in rabbits receiving repeated injections of  $T_4$  has been reported by Sinha *et al.* (1982).

The data on the content of  $T_4$  and  $T_3$  in the serum are given in table 2. It may be noticed that treatment with  $T_3$  brought about a 50–57% decrease in serum  $T_4$  levels. Lower dose of  $T_3$  (0.5 µg) resulted in a small but reproducible increase in

**Table 2.** Effect of experimental thyrotoxicosis on serum T<sub>3</sub> and T<sub>4</sub> levels.

Treatment	T <sub>4</sub> (µg/dl)	T <sub>3</sub> (ng/dl)
Control	6.80 ± 0.81	120.4 ± 4.3
0.5 µg T <sub>3</sub>	3.40 ± 0.32* <sup>a</sup>	134.0 ± 1.87**
1.0 µg T <sub>3</sub>	2.94 ± 0.14***	1560.0 ± 67.82****
0.5 µg T <sub>4</sub>	9.40 ± 1.10 <sup>NS</sup>	752.0 ± 14.97****
1.0 µg T <sub>4</sub>	15.70 ± 1.03****	1100.0 ± 57.01****

Experimental details are as given in table 1.

Results are given as mean ± SEM of 5 independent observations.

\**P* < 0.01, \*\**P* < 0.02, \*\*\**P* < 0.002 and \*\*\*\**P* < 0.001 compared with control.

NS, Not significant.

serum T<sub>3</sub> levels (11% increase) while at the higher dose of 1 µg, the increase in serum T<sub>3</sub> levels was 13-fold. Levels of serum T<sub>4</sub> increased steadily with increasing doses of injected T<sub>4</sub> and amounted to 38 and 130% increase at the two doses employed. Serum T<sub>3</sub> levels also increased by 6-9-fold under these conditions.

The effect of thyrotoxicosis on protein content in the heart and the yield of mitochondrial proteins was next examined. These results are given in table 3. It can be seen that both T<sub>3</sub> as well as T<sub>4</sub> treatment caused significant increase in the protein content in the heart (23–86% increase) with only marginal changes in the yield of mitochondrial proteins except in the case of higher doses of T<sub>4</sub> where this value increased by almost 75%.

**Table 3.** Effect of thyrotoxicosis on protein content and mitochondrial yield in rat heart.

Treatment	Tissue protein content (mg/g tissue)	Yield of mitochondrial protein (mg/g tissue)
Control (4)	135 ± 9	10.0 ± 0.6
0.5 µg T <sub>3</sub> (4)	182 ± 6*	7.2 ± 0.6**
1.0 µg T <sub>3</sub> (4)	182 ± 3***	9.0 ± 0.8 <sup>NS</sup>
0.5 µg T <sub>4</sub> (5)	167 ± 2**	8.6 ± 0.4 <sup>NS</sup>
1.0 µg T <sub>4</sub> (5)	251 ± 15****	18.1 ± 0.8****

Experimental details are as given in table 1.

Results are given as mean ± SEM of number of observations indicated in the parentheses.

\**P* < 0.01, \*\**P* < 0.02, \*\*\**P* < 0.002 and \*\*\*\**P* < 0.001 compared with control.

NS, Not significant.

The results on effects of thyrotoxicosis on oxidative phosphorylation are given in tables 4–7. The data in table 4 summarize the effects of thyrotoxicosis on oxidative phosphorylation in rat heart mitochondria with glutamate, as the substrate. It is evident that T<sub>3</sub> treatment resulted in approximately 70–76% decrease in the state 3 respiration rate. Effects of T<sub>4</sub>, on the other hand, were apparent only at the higher

**Table 4.** Effect of thyrotoxicosis on oxidative phosphorylation in rat heart mitochondria with glutamate as substrate.

Treatment	ADP/O ratio	Respiration rate (nmol O <sub>2</sub> /min/mg protein)		ADP-phosphorylation rate (nmol/min/mg protein)
		+ADP <sub>p</sub>	-ADP	
Control (8)	3.0 ± 0.12	72.8 ± 5.0	9.8 ± 1.2	424.0 ± 17.1
0.5 µg T <sub>3</sub> (8)	2.6 ± 0.11	17.4 ± 1.3***	7.6 ± 0.6 <sup>NS</sup>	95.4 ± 3.3***
1.0 µg T <sub>3</sub> (8)	3.1 ± 0.05	21.6 ± 1.3***	5.6 ± 0.3*	133.2 ± 12.1***
0.5 µg T <sub>4</sub> (10)	3.1 ± 0.09	73.4 ± 4.6 <sup>NS</sup>	8.5 ± 1.2 <sup>NS</sup>	448.6 ± 19.8 <sup>NS</sup>
1.0 µg T <sub>4</sub> (8)	3.1 ± 0.08	48.8 ± 5.3*	4.6 ± 0.6**	294.6 ± 27.8**

Measurements of respiration rates were carried out at 25°C with a Clark-type oxygen electrode, employing a medium (total volume 1.3 ml) containing 225 mM sucrose, 20 mM KCl, 1 mM EGTA, 10 mM MOPS, pH 7.4 and 5 mM potassium phosphate buffer, pH 7.4. Calculations of state 3 and state 4 respiration rates, ADP/O ratio and ADP-phosphorylation rates were as described in the text.

Results are given as mean ± SEM of the number of observations indicated in the parentheses.

\* $P < 0.01$ , \*\* $P < 0.002$  and \*\*\* $P < 0.001$  compared with control.

NS, Not significant.

**Table 5.** Effect of thyrotoxicosis on oxidative phosphorylation in rat heart mitochondria using pyruvate + malate as the substrate.

Treatment	ADP/O	Respiration rate (nmol O <sub>2</sub> /min/mg protein)		ADP-phosphorylation rate (nmol/min/mg protein)
		+ADP	-ADP	
Control (10)	3.0 ± 0.10	105.1 ± 5.9	19.1 ± 1.1	630.9 ± 42.0
0.5 µg T <sub>3</sub> (8)	3.1 ± 0.07	48.3 ± 3.1***	13.8 ± 0.2***	297.0 ± 22.9***
1.0 µg T <sub>3</sub> (8)	3.3 ± 0.06	56.0 ± 2.1***	10.0 ± 0.5***	371.4 ± 20.4***
0.5 µg T <sub>4</sub> (10)	3.0 ± 0.07	74.0 ± 4.1***	12.5 ± 0.9***	441.6 ± 29.7**
1.0 µg T <sub>4</sub> (8)	3.0 ± 0.06	76.1 ± 3.3***	11.8 ± 0.8***	457.7 ± 23.6*

Experimental details are as described in tables 1 and 4.

Results are given as mean ± SEM of the number of observations indicated in the parentheses.

\* $P < 0.01$ , \*\* $P < 0.002$  and \*\*\* $P < 0.001$  compared with control.

NS, Not significant.

dose of 1 µg with a 33% decrease in the state 3 respiration rate. The state 4 respiration rates also decreased correspondingly but to a lesser extent following T<sub>3</sub> treatment so that the values of respiratory control ratios (RCR) were low in T<sub>3</sub>-treated rats. By contrast, these values were somewhat higher for T<sub>4</sub>-treated animals (data not given). The ADP/O ratios were in normal range but ADP-phosphorylation rates decreased from 30-78% which is a reflection of decreased state 3 respiration rates.

When pyruvate + malate was employed as the substrate pair (table 5), the state 3 respiration rates decreased from 48-54% with T<sub>3</sub> treatment and from 28-30% with T<sub>4</sub> treatment respectively with corresponding decreases in state 4 respiration rates. Consequently, the RCR values were more or less unchanged (data not given). Thus the effects of thyrotoxicosis seemed to be different on pyruvate and malate than those seen for glutamate above (table 4). The ADP/O ratios were not altered.

**Table 6.** Effect of thyrotoxicosis on oxidative phosphorylation in rat heart mitochondria using succinate as the substrate.

Treatment	ADP/O ratio	Respiration rate (nmol O <sub>2</sub> /min/mg protein)		ADP-phosphorylation rate (nmol/min/mg protein)
		+ADP	-ADP	
Control (10)	1.3 ± 0.08	245.1 ± 8.5	136.0 ± 12.1	614.1 ± 37.8
0.5 µg T <sub>3</sub> (10)	1.1 ± 0.07	155.6 ± 3.3***	104.2 ± 5.6*	318.0 ± 22.6***
1.0 µg T <sub>3</sub> (10)	1.2 ± 0.10	132.1 ± 4.2***	85.8 ± 5.7**	304.5 ± 28.5***
0.5 µg T <sub>4</sub> (10)	1.4 ± 0.06	222.8 ± 9.8 <sup>NS</sup>	108.6 ± 10.5 <sup>NS</sup>	637.5 ± 23.4 <sup>NS</sup>
1.0 µg T <sub>4</sub> (8)	1.3 ± 0.07	156.8 ± 9.8***	78.7 ± 7.7**	398.5 ± 28.3***

Experimental details are as described in tables 1 and 4.

Results are given as mean ± SEM of the number of observations indicated in the parentheses.

\*P < 0.05, \*\*P < 0.002 and \*\*\*P < 0.001 compared with control.

NS, Not significant.

**Table 7.** Effect of thyrotoxicosis on oxidative phosphorylation in rat heart mitochondria using ascorbate + TMPD as the substrate.

Treatment	ADP/O ratio	Respiration rate (nmol O <sub>2</sub> /min/mg protein)		ADP-phosphorylation rate (nmol/min/mg protein)
		+ADP	-ADP	
Control (10)	0.33 ± 0.004	370.5 ± 14.6	179.6 ± 8.3	249.3 ± 9.6
0.5 µg T <sub>3</sub> (8)	0.32 ± 0.007	127.9 ± 7.8*	92.6 ± 3.2*	81.4 ± 5.5
1.0 µg T <sub>3</sub> (8)	0.33 ± 0.017	145.4 ± 9.2*	96.2 ± 8.0*	94.8 ± 6.2*
0.5 µg T <sub>4</sub> (10)	0.37 ± 0.050	254.6 ± 7.5*	114.8 ± 4.8*	191.3 ± 5.8*
1.0 µg T <sub>4</sub> (8)	0.37 ± 0.009	137.5 ± 3.3*	95.8 ± 6.7*	100.3 ± 2.9*

Experimental details are as described in tables 1 and 4.

Results are given as mean ± SEM of the number of observations indicated in the parentheses.

\*P < 0.001 compared with control.

However, as in the case of glutamate, the ADP-phosphorylation rates decreased significantly from 28–53%, the effects being more pronounced with T<sub>3</sub> treatment.

With succinate as the respiratory substrate, the state 3 respiration rates decreased by 37–46% and 9–36% respectively with T<sub>3</sub> and T<sub>4</sub> in a dose-dependant manner. Similar pattern was also noted for the state 4 respiration rates and the extent of decrease was 23–37% and 20–42% respectively (table 6).

For ascorbate + TMPD (table 7), T<sub>3</sub>-toxicosis caused 61–66% decrease in the state 3 respiration rates with a concomitant 46–48% decrease in the state 4 respiration rates. Interestingly, with T<sub>4</sub>, both state 3 and state 4 respiration rates decreased in a dose-dependant manner by 31–63% and 36–42% respectively. The general effects of thyrotoxicosis therefore seem to be decreased state 3 respiration which was substrate specific and thyroid hormone dose-dependant which was also reflected in terms of the ADP-phosphorylation. The ADP/O ratios and respiratory control ratios (data not given) were generally not affected by thyrotoxicosis.

The contents of mitochondrial cytochromes as affected by thyrotoxicosis are given in table 8. It may be noted that treatment with T<sub>3</sub> as well as T<sub>4</sub> caused 20–29% decrease in the cytochrome aa3 content. The contents of cytochromes c + c<sub>1</sub> also decreased somewhat following treatment with T<sub>3</sub> and higher doses of

**Table 8.** Effect of thyrotoxicosis on the mitochondrial cytochrome contents.

Treatment	Cytochrome content, nmol/mg mitochondrial protein		
	aa <sub>3</sub>	b	c + c <sub>1</sub>
Control (10)	0.624 ± 0.024	0.384 ± 0.024	0.854 ± 0.023
0.5 µg T <sub>3</sub> (8)	0.442 ± 0.016***	0.345 ± 0.027*	0.758 ± 0.027**
1.0 µg T <sub>3</sub> (8)	0.499 ± 0.015***	0.455 ± 0.018**	0.765 ± 0.025**
0.5 µg T <sub>4</sub> (6)	0.448 ± 0.030***	0.390 ± 0.046 <sup>NS</sup>	0.907 ± 0.058 <sup>NS</sup>
1.0 µg T <sub>4</sub> (10)	0.451 ± 0.017***	0.361 ± 0.029 <sup>NS</sup>	0.653 ± 0.045***

Experimental details are as given in table 1 and described in the text. Contents of cytochromes were calculated from the difference spectra as described in the text. Results are given as mean ± SEM of number of observations indicated in the parentheses.

\* $P < 0.05$ , \*\* $P < 0.02$  and \*\*\* $P < 0.01$  compared with control.

NS, Not significant.

T<sub>4</sub> (11–24% decrease). Cytochrome b content, however, increased at 1 µg T<sub>3</sub> dose by about 19 %, while registering a decrease at a low dose of T<sub>3</sub> (10% decrease). Treatment with T<sub>4</sub> had no effect on cytochrome b content.

## Discussion

These studies assume importance because in human patients thyrotoxic condition is known to cause severe cardiac dysfunctions including tachycardia, anxiety, palpitation, loss of weight and general muscular weakness (Williams and Bakke, 1982). Effect of thyrotoxicosis on mitochondrial functions have, been investigated earlier by other researchers in various tissues. Some of these workers, however, have employed excessively higher doses of either T<sub>3</sub>- or T<sub>4</sub>- (Maley and Lardy, 1953; Hoch and Lipmann, 1954). Gustafsson *et al.* (1965) using hypothyroid rats concluded that thyroid hormones were required for maintaining the synchrony of turnover of mitochondrial protein components in the skeletal muscle. Holloszy and co-workers (Booth and Holloszy, 1975; Winder *et al.*, 1975; Winder and Holloszy, 1977) have concluded that thyrotoxicosis did not cause impairment of energy metabolism in the skeletal muscle, although turnover of cytochrome c was significantly influenced by thyroid-hormone-status. Stocker *et al.* (1968) concluded that thyrotoxicosis in dogs did not significantly influence energy metabolism in skeletal muscle mitochondria. Dow (1967) also did not find any aberration in the function of skeletal muscle mitochondria from thyrotoxic rats.

There are, not many reports in literature on the thyrotoxicosis effects on mitochondrial function of heart which comprises of specialized muscle tissue. Most of the investigators have directed their efforts to investigate effects of thyrotoxicosis on sarcolemmal and myosin ATPase activities (Goodkind *et al.*, 1974; Edelman and Ismail-Beigi, 1974; Banerjee *et al.*, 1976; Lo and Edelman, 1976; Curfman *et al.*, 1977; Litten *et al.*, 1981; Chizzonite *et al.*, 1982; Dillmann, 1982, 1985; Sinha *et al.*, 1982).

The investigations on energy metabolism reported in literature, were carried out employing either T<sub>3</sub>- or T<sub>4</sub>-thyrotoxicosis, at widely varying dose levels (Hoch and Lipmann, 1954; Dow, 1967; Booth and Holloszy, 1975; Winder *et al.*, 1975). In the



present investigation, an attempt has been made to examine systematically the dose-dependant effects of  $T_3$ - and  $T_4$ -thyrotoxicosis. These studies assume relevance since in human patients, cases of  $T_3$ -,  $T_4$ - and combined  $T_3$ - $T_4$ - thyrotoxicosis have been reported (Nikkila and Pitkanen, 1959; Lin and Nankin, 1980).

The present studies had to be restricted to a lower dose of the hormones since higher doses led to excessive hyperthermia, tachycardia and increased mortality rate. Nevertheless, the present studies have brought forth the significant observations that toxicosis induced by  $T_3$ -resulted in a severe impairment of active state 3 respiration in the cardiac mitochondria than did  $T_4$ -thyrotoxicosis, with most of the substrates examined excepting ascorbate + TMPD. Interestingly the effects were substrate specific and depended on the dose of  $T_3$  or  $T_4$  (tables 4-7). The net result was impaired rate of ATP synthesis with all the substrates employed. The enhanced contractile response of the hyperthyroid heart referred to above and the impaired rate of ATP synthesis as observed in the present studies may explain the fatigue in the cardiac muscle leading to the congestive heart failure. Another interesting feature was, unlike in case of other tissues such as liver, kidney and brain (Hoch and Lipmann, 1954; Satav and Katyare, 1982), heart mitochondria were not uncoupled *i.e.*, their ADP/O-ratios did not decrease with any of the substrates studied. This is similar to reported observations for skeletal muscle mitochondria (Dow, 1967; Stocker *et al.*, 1968). The impairment or dysfunction therefore seems to be localized to the electron transport system rather than the phosphorylating machinery of the mitochondria.

The decreased contents of cytochromes  $aa_3$  and  $c + c_1$  can but only partly explain the decreased respiration rates. In this connection, it is interesting to note that  $T_3$ -thyrotoxicosis resulted in a generalized decrease in the contents of cytochromes  $aa_3$  and  $b$  with a concomitant increase in the  $c + c_1$  component in liver and kidney mitochondria (Winder *et al.*, 1975; Winder and Holloszy, 1977; Satav and Katyare, 1982). Impaired primary dehydrogenase functions would therefore seem to be an interesting possibility to explore. It may however be pointed out here that thyroidectomy did not result in any significant changes in the primary dehydrogenases levels in tissues such as liver, kidney and brain (Katyare *et al.*, 1977). However, Dave *et al.* (1989) have shown that the kinetic properties of succinate oxidase and ATPase change significantly in thyrotoxicosis.

Examination of  $T_4$  and  $T_3$  content in serum (table 2) revealed that  $T_3$  treatment, on the one hand, suppressed serum  $T_4$  levels while elevating the  $T_3$  levels.  $T_4$  treatment, on the other hand, resulted in an overall increase in the serum levels of  $T_3$  and  $T_4$ . However, the increase in  $T_3$  level was not of the same magnitude as in the case of  $T_3$  treatment. These observations are in agreement with those on respiration effects, and point out to an inverse relationship between serum  $T_3$  level and the respiratory activity. Serum  $T_4$  levels would therefore seem to play a less significant role in influencing the respiratory activity. Interestingly, in other studies it has been observed that  $T_4$  rather than  $T_3$  plays a prominent role in influencing the respiratory activity in rat brain (Katyare, S. S., unpublished results). It is interesting to note in this connection that recently it has been shown that tissue levels of  $T_3$  and  $T_4$  are important for tissue functions (Obregon *et al.*, 1981). It is possible that in thyrotoxicosis the heart tissue may accumulate disproportionately high amounts of  $T_3$  and  $T_4$  leading to mitochondrial dysfunction. Interestingly however, no catabolic influence (Winder *et al.*, 1975; Winder and Holloszy, 1977;

Carter *et al.*, 1981; Satav and Katyare, 1981; Carter *et al.*, 1982; Cote' and Boulet, 1985) on tissue protein synthesis was seen since increased protein content and cardiac hypertrophy were already evident under these conditions (table 2).

## References

- Banerjee, S. K., Fluik, I. L. and Markin, E. (1976) *Circ. Res.*, **39**, 319.
- Bernal, J. and De Groot, L. J. (1980) in *Thyroid gland* (ed. M. De Visscher) (New York: Reven Press) p. 123.
- Booth, F. W. and Holloszy, J. O. (1975) *Arch. Biochem. Biophys.*, **167**, 674.
- Carter, W. J., Benjamin, W. S. and Faas, F. H. (1981) *Biochem. J.*, **194**, 685.
- Carter, W. J., Benjamin, W. S. and Faas, F. H. (1982) *Biochem. J.*, **204**, 69.
- Channide, B. J., Adlin, F. V., Marks, A. D., Denenberg, P. S., Me Donough, M. T., Chakko, G. S. and Spann, J. F. (1981) *New Engl. J. Med.*, **305**, 497.
- Chizzonite, R. A., Everett, A. W., Clark, W. A., Jakovcic, S., Rabinowitz, M. and Zak, R. (1982) *J. Biol. Chem.*, **257**, 2056.
- Cote', C. and Boulet, D. (1985) *Biochem. Biophys. Res. Commun.*, **128**, 1425.
- Curfman, G. D., Grawley, T. J. and Smith, T. W. (1977) *J. Clin. Invest.*, **59**, 586.
- Dave, B. N., Billimoria, F. R. and Katyare, S. S. (1989) *J. Biosci.*, **14**, 341.
- Dillmann, W. H. (1982) *Metabolism*, **31**, 199.
- Dillmann, W. H. (1985) *Edocrinology*, **116**, 2160.
- Doussiere, J., Ligeti, E., Brandoten, G. and Vignais, P. V. (1984) *Biochim. Biophys. Acta*, **766**, 492.
- Dow, D. S. (1967) *Biochemistry*, **6**, 3350.
- Edelman, I. S. and Ismail-Beigi, F. (1974) *Rec. Prog. Hormone Res.*, **30**, 235.
- Ferreira, J. and Gil, L. (1984) *Biochem. J.*, **218**, 61.
- Goodkind, M. J., Dambach, G. F., Thyrum, P. T. and Luchi, R. J. (1974) *Am. J. Physiol.*, **226**, 66.
- Gustafsson, R., Tata, J. R., Lindberg, O. and Ernster, L. (1965) *J. Cell Biol.* **26**, 555.
- Hoch, F. L. and Lipmann, F. (1954) *Proc. Natl. Acad. Sci. USA*, **40**, 909.
- Hoffman, I. and Lowery, R. D. (1960) *Am. J. Cardiol.*, **6**, 893.
- Irvine, W. J., Lamberg, B. A., Cullen, D. R. and Gordon, R. (1979) *J. Clin. Lab. Immunol.*, **2**, 349.
- Jabbari, B. and Huott, A. D. (1980) *Epilepsia*, **21**, 91.
- Johansen, K., Hannsen, J. M. and Skovsted, L. (1978) *Acta. Med. Scand.*, **204**, 361.
- Katyare, S. S., Fatterpaker, P. and Sreenivasan, A. (1970) *Biochem. J.*, **118**, 111.
- Katyare, S. S., Joshi, M. V., Fatterpaker, P. and Sreenivasan, A. (1977) *Arch. Biochem. Biophys.*, **182**, 155.
- Lin, T. and Nankin, H. R. (1980) *Horm. Metab. Res.*, **12**, 611.
- Litten, R. Z., Martin, B. J., Howe, E. R., Alpert, N. R. and Solare, R. J. (1981) *Circ. Res.*, **48**, 498.
- Lo, C. S. and Edelman, I. S. (1976) *J. Biol. Chem.*, **251**, 7834.
- Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J. (1951) *J. Biol. Chem.*, **193**, 265.
- Maley, G. F. and Lardy, H. A. (1953) *J. Biol. Chem.*, **204**, 435.
- Mela-Riker, L. W. and Bukoski, R. D. (1985) *Annu. Rev. Physiol.* **47**, 645.
- Nikkila, E. A. and Pitkanen, E. (1959) *Acta Endocrinol.*, **31**, 573.
- Obregon, M. J., Mallol, I., Escobar, del Rey, F. and Morreale de Escobar, G. (1981) *Endocrinology*, **109**, 908.
- Oppenheimer, J. H. (1979) *Science*, **203**, 971.
- Oppenheimer, J. H., Schawartz, H. I., Surks, M. L., Koerner, D. and Dillmann, W. H. (1976) *Rec. Prog. Hormone Res.*, **32**, 529.
- Satav, J. G. and Katyare, S. S. (1981) *Experientia*, **37**, 100.
- Satav, J. G. and Katyare, S. S. (1982) *Mol. Cell. Endocrinol.*, **28**, 173.
- Shapiro, S., Steier, M. and Dimich, I. (1975) *Clin. Pediatr. (Bologna)*, **14**, 1155.
- Sinha, A. M., Umeda, P. K., Kavinsky, C. J., Rajamanickman, C., Hsu, H. J., Jakovcic, S. and Rabinowitz, M. (1982) *Proc. Natl. Acad. Sci. USA*, **79**, 5847.
- Stocker, W. W., Samaha, F. J. and De Groot, L. J. (1968) *Am. J. Physiol.*, **44**, 900.
- Tata, J. R. (1964) in *Action of hormones on molecular process* (eds G. Litwack and D. Kritschewsky) (New York: Wiley) p. 58.

- Tata, J. R., Ernster, L., Lindberg, O., Arrhenius, E., Pedersen, S. and Hedman, R. (1963) *Biochem. J.*, **86** 408.
- De Visscher, M. and Burger, A. (1980) in *Thyroid gland* (ed. M. De Visscher) (New York: Raven Press) p. 169.
- Williams, R. H. and Bakke, J. L. (1962) in *Text book of endocrinology* (ed. R. H. Williams) (Philadelphia: W. B. Saunders Co.) p. 96.
- Winder, W. W., Baldwin, K. M., Terjung, R. L. and Holloszy, J. O. (1975) *Am. J. Physiol.*, **228**, 1341.
- Winder, W. W. and Holloszy, J. O. (1977) *Am. J. Physiol.*, **232**, C 180.